Efficacy and safety of retinol palmitate ophthalmic solution in the treatment of dry eye: a Japanese Phase II clinical trial

Abstract

Purpose

The purpose of this study was to investigate the efficacy and safety of the administration of retinol palmitate (VApal) ophthalmic solution (500 IU/mL) for the treatment of patients with dry eye.

Patients and methods

This study included 66 patients with dry eye. After a 2-week washout period, patients were randomized (1:1) into either a VApal ophthalmic solution or a placebo group, and a single drop of either solution was administered six times daily for 4 weeks. Efficacy measures were 12 subjective symptoms, rose bengal (RB) and fluorescein staining scores, tear film breakup time, and tear secretion. Safety measures included clinical blood and urine analyses and adverse event recordings.

Results

In comparisons of the two groups, the mean change in RB staining score from baseline was significantly lower in the VApal group at 2 and 4 weeks (P<0.05 and P<0.01, respectively). Furthermore, the fluorescein clearance rate (fluorescein staining score) was significantly higher in the VApal group at 4 weeks (P<0.05). The VApal group showed a significant improvement in blurred vision at 1 and 2 weeks (P<0.01 and P<0.05, respectively), and the mean change in the total score for subjective symptoms from baseline was significantly lower in the VApal group at 1 week (P<0.05). In before- and after-intervention comparisons, the fluorescein and RB staining scores showed improvement in both groups. Improvement was noted for 11 subjective symptoms in the VApal group and for seven symptoms in the placebo group. No significant differences in adverse events and reactions were found between the groups.

Conclusion

VApal ophthalmic solution (500 IU/mL) is safe and effective for the treatment of patients with dry eye.

Keywords:

• vitamin A
• cornea
• conjunctiva
• tear
• mucin

View correction statement:

Efficacy and Safety of Retinol Palmitate Ophthalmic Solution in the Treatment of Dry Eye: A Japanese Phase II Clinical Trial [Corrigendum]

Introduction

The International Dry Eye Workshop defines dry eye as “a multifunctional disease of tears and ocular surface that results in symptoms such as ocular discomfort, visual disturbance, and tear film instability with potential damage to the ocular surface”.¹ The number of patients with dry eye has increased owing to the wearing of contact lenses and long-term use of personal computers and smartphones, which decrease tear secretion, increase evaporation of tear, and change tear composition.²

Dry eye occurs when mucin levels decrease due to corneal and conjunctival disorders. This change impairs the stabilization of the aqueous layer on the mucin layer, and the tear film on the ocular surface becomes unstable and cannot be uniformly maintained.^3–5 In dry eye, destabilization of the mucin layer becomes a vicious cycle, leading to further corneal and conjunctival epithelial disorders. Therefore, a reduction in mucin and its accompanying abnormalities correlates with the onset and progression of dry eye.⁶

Hyaluronic acid is produced by corneal epithelial cells and promotes the adhesion, extension, and migration of corneal epithelial cells, thereby playing a role in repairing corneal epithelial cells damaged by dry eye.⁷ Therefore, treatments for dry eye must promote mucin production, proliferation of mucin-producing conjunctival goblet cells, and production of hyaluronic acid by corneal epithelial cells for wound healing.

Our previous investigations of the pharmacological action of retinol palmitate (VApal) showed that VApal promotes the production of hyaluronic acid⁷ and mucin.⁸ Furthermore, in studies using animal models for dry eye, we found that the administration of 500–1,500 IU/mL VApal improved corneal epithelial disorders^9,10 and mucin covering disorders^10,11 and aided in the recovery of conjunctival goblet cell numbers.^9–11 Moreover, VApal was confirmed to promote mucin gene and protein expression during the healing of corneal conjunctival wounds.¹²

The clinical efficacy of VApal in the treatment of keratoconjunctival disease has also been investigated in clinical studies. According to previous reports, the administration of 500–1,000 IU/mL VApal improved subjective symptoms, clinical symptoms, and cytological findings in dry eyes; superior limbic keratoconjunctivitis; conjunctival dyskeratosis; and other diseases of the cornea and conjunctiva.^13–17

From these results, we hypothesized that VApal would improve dry eye and its subjective symptoms, and we developed a formulation containing 500 IU/mL VApal. To demonstrate the clinical efficacy and safety of ophthalmic solution containing 500 IU/mL VApal in the treatment of patients with dry eye, we performed a multicenter, placebo-controlled, randomized, double-blind, parallel-group comparison.

Patients and methods

This trial was jointly conducted by researchers at six facilities. The ethical and scientific validity of the study was assessed and approved by the Institutional Review Boards of Juntendo University Hospital, Juntendo Tokyo Koto Geriatric Medical Center, Yokohama Minoru Clinic. This trial complied with the Declaration of Helsinki. Before the trial began, we explained the complete study procedure and anticipated adverse reactions to all patients and obtained their written informed consent. The study was registered before patient enrollment (clinical trial identifier JapicCTI-152829; accessed March 3, 2015).

Subjects

The subjects were outpatients of both sexes aged 15 years or older. In all subjects, at least one eye had a confirmed diagnosis of dry eye on the same side both before and after a washout period, and the subjective symptom score for “eye dryness” was ≥2 according to the criteria of the Evaluation of Subjective Symptoms section given later.

The diagnostic criteria (2006) of the Dry Eye Study Group were used to diagnose dry eyes.^18,19 Patients meeting all the following three criteria were included: 1) presence of subjective symptoms; 2) fluorescein staining score of ≥3 points (total 9 points) and rose bengal (RB) staining score of ≥3 points (total 9 points); and 3) Schirmer’s test value of ≤5 mm in 5 min or tear film breakup time (BUT) of ≤5 s. Patients were excluded if they had a history of Stevens–Johnson syndrome, toxic epidermal necrolysis, ocular cicatricial pemphigoid, chemical or thermal burns, allogeneic hematopoietic stem cell transplantation, refractive corneal surgery, or contact lens use. Patients were also excluded if they had other ocular diseases, any systemic diseases or medication use that would cause dry eye, or were pregnant, lactating, or planning to become pregnant at the time of this study.

Study design

This study was a multicenter, placebo-controlled, randomized, double-masked, parallel-group Phase II clinical study. The study protocol was designed with a 2-week washout period during which a single drop of preservative-free artificial tear was administered six times daily for 2 weeks. Patients meeting the dry eye diagnostic criteria before and after the washout period were randomly assigned to either a VApal ophthalmic solution or a placebo ophthalmic solution group at a ratio of 1:1 and then double blinded. One drop of VApal or placebo was administered six times daily for 4 weeks, and efficacy and safety were examined at various time points during administration. The VApal ophthalmic solution contained VApal and D-α-tocopherol acetate as active ingredients and hypromellose as an inactive ingredient. The VApal ophthalmic solution was prepared by solubilization of VApal with a surfactant, which may enhance penetration of VApal into the cornea and conjunctiva. The placebo ophthalmic solution contained base only (D-α-tocopherol acetate and hypromellose). The VApal ophthalmic solution was stable for 6 weeks at room temperature after opening and was kept refrigerated during the test period.

Efficacy was evaluated at the start of drug administration and after 1, 2, and 4 weeks (or at the time of discontinuation, if applicable) of the drug administration. The evaluation assessed objective signs (fluorescein and RB staining scores, BUT) and subjective symptoms. Tear secretion measured with Schirmer’s test was evaluated as an objective sign at the beginning of drug administration and at 4 weeks (or discontinuation) after the drug administration.

The changes in the subjective symptom score for eye dryness, fluorescein staining score, and RB staining score at the end of drug administration (4 weeks or at discontinuation) were set as primary end points.

Safety was assessed with slit-lamp examination, visual acuity testing, intraocular pressure measurement, funduscopic examination, and clinical blood and urine analyses. Slit-lamp examination was performed at every visit, and the other assessments were performed at the beginning of the washout period and after 4 weeks of administration (or the time of discontinuation).

Ocular surface evaluation

Fluorescein staining score

To obtain the fluorescein staining score, we administered 20 μL of 0.6% fluorescein solution. The cornea was divided into three sections (upper, middle, and lower), and the staining in each was scored from 0 (no damage) to 3 (damage in the entire area). The total score was calculated by adding the scores for each area.²⁰

RB staining score

To obtain the RB staining score, we administered 20 μL of 1% RB solution. The cornea and conjunctiva were divided into five sections (nasal and temporal conjunctival areas and upper, middle, and lower corneal areas), and the staining in each was scored from 0 (no damage) to 3 (damage in the entire area). The total score was calculated by adding the scores for each area.²⁰

BUT

BUT was measured three times with a stopwatch, and the mean value of the measurements was calculated.

Schirmer’s test

Schirmer’s test was performed without anesthesia to measure tear volume as follows. A Schirmer’s test strip was placed on the lower eyelid without touching the cornea. The tear volume was then measured for 5 min. The length of tear fluid absorbed on the strip measured in millimeters from the edge of the strip was recorded as tear volume.

Evaluation of subjective symptoms

A physician interviewed patients and evaluated 12 subjective symptoms (dryness, eye fatigue, foreign body sensation, blurred vision, eye pain, photophobia, heaviness, itching, ocular discomfort, eye discharge, tearing, and hyperemia). The total score of the subjective symptoms was calculated as the change in the sum of the subjective symptom scores for dryness, foreign body sensation, blurred vision, photophobia, and eye pain. These symptoms were scored from 0 to 4, in which a score of 0 indicated no symptoms and a score of 4 indicated severe symptoms.

Safety evaluation

The evaluation of safety was assessed with slit-lamp examination, visual acuity testing, intraocular pressure measurement, funduscopic examination, and clinical blood and urine analyses. A physician identified adverse events from the findings of these evaluations. Patients were interviewed at each visit to confirm the presence or absence of adverse events. Adverse reactions were considered if a reasonable possibility that a causal relationship existed between the drug and the adverse event, and the physician judged that the causal relationship cannot be denied.

Statistical analysis

Data are shown as mean ± standard error. Monocular data analyses of the eligible eyes were performed for statistical comparisons. The changes in fluorescein staining score, RB staining score, subjective symptoms, total score for subjective symptoms, BUT, and Schirmer’s test value were determined using the scores obtained at the beginning of drug administration and at each measurement time point during the study period. Statistical differences between VApal and placebo groups were evaluated using the unpaired t-test. In before- and after-intervention comparisons between the two groups, a corresponding t-test was used. For the analysis of fluorescein and RB clearance rate (fluorescein and RB staining score), the percentage of cases in which the score disappeared was compiled for each treatment group, and comparisons between groups were conducted with the Fisher’s exact test. JMP ver.12 (SAS Institute Inc., Cary, NC, USA) was used for statistical analysis.

Results

Participant characteristics

A total of 96 patients were enrolled. In all, 30 patients discontinued the study during the washout period before drug administration. A total of 66 patients were randomly assigned to each group as follows: 33 to the VApal group and 33 to the placebo group. The mean age of the participants was 49.0±18.0 years with a range of 19–77 years. There were six males and 60 females.

There were no cases of withdrawal or dropout in this trial. Therefore, medication administration ended after 4 weeks in all patients (Table 1). There were no statistically significant differences between the groups with respect to the clinical characteristics of the patients in each group, sex, age, distribution of Sjögren’s syndrome, or severity of dry eye (fluorescein staining scores, RB staining scores, BUT, Schirmer’s test values; Table 2).

Table 1 Patient disposition

	Total (n)	Placebo (n)	VApal (n)
Randomized and treated	66	33	33
Completed	66	33	33
Discontinued	0	0	0

Abbreviation: VApal, retinol palmitate.

Table 2 Baseline demographics and clinical characteristics

	Placebo	VApal
Sex, female	30 (90.9%)	30 (90.9%)
Age (years)	45.8±19.0	52.1±16.7
Sjögren’s syndrome	3 (9.1%)	3 (9.1%)
Fluorescein staining score (points)	2.3±1.5	2.2±1.8
RB staining score (points)	3.1±1.8	3.5±1.6
BUT (s)	3.70±1.35	3.40±1.15
Schirmer’s test value (mm)	7.8±8.2	10.3±10.4

Note: Values are expressed as n (%) or mean ± SD.

Abbreviations: VApal, retinol palmitate; RB, rose bengal; BUT, tear film breakup time.

Ocular surface findings and tear functions

Changes in fluorescein staining score

Figure 1A shows the changes from the baseline fluorescein staining score at all follow-up points in each group. Significant differences were observed at 2 and 4 weeks after administration (VApal: 2 weeks, P=0.0079; 4 weeks, P=0.0037 and placebo: 2 weeks, P=0.0459; 4 weeks, P=0.0052). The mean change in the fluorescein staining score at 1, 2, and 4 weeks was higher than that in the placebo group at all evaluation points, but the difference did not reach significance.

Figure 1 Mean change in staining score.

Notes: Mean change in fluorescein staining score (A) and RB staining score (B) from baseline to 1, 2, and 4 weeks. *P<0.05. **P<0.01 versus placebo (unpaired t-test).
Abbreviations: RB, rose bengal; VApal, retinol palmitate.

Changes in RB staining score

Figure 1B shows the changes from the baseline RB staining score at all follow-up points in each group. Significant differences were observed at 2 and 4 weeks after administration (2 weeks, P<0.0001; 4 weeks, P<0.0001) in the VApal group and at 4 weeks (P=0.0446) in the placebo group. The mean change in RB staining score at 1, 2, and 4 weeks was higher in the VApal group than in the placebo group at all evaluation points. Compared with the placebo group, the VApal group showed a significant decrease in RB score at 2 and 4 weeks after drug administration.

The clearance rates of fluorescein staining score

Figure 2A shows that the clearance rates of the fluorescein staining score at 1, 2, and 4 weeks were 6.1%, 15.2%, and 24.2% in the VApal group and 9.1%, 6.1%, and 3.0% in the placebo group, respectively. Significant differences were observed between the groups at 4 weeks.

Figure 2 Clearance rates of staining score.

Notes: Clearance rates of the fluorescein staining score (A) and RB staining score (B) at 1, 2, and 4 weeks. *P<0.05 versus placebo (Fisher’s exact test).
Abbreviations: RB, rose bengal; VApal, retinol palmitate.

The clearance rates of RB staining score

Figure 2B shows that the clearance rates of the RB staining score at 1, 2, and 4 weeks of drug administration were 3.0%, 6.1%, and 24.2% in the VApal group and 3.0%, 6.1%, and 6.1% in the placebo group, respectively. The clearance rate was higher in the VApal group at 4 weeks, but no significant difference was observed between the groups.

BUT

At each evaluation point, the mean change in BUT was higher in the VA group than in the placebo group, but the difference did not reach significance.

Schirmer’s test

No significant difference in the mean change in the Schirmer’s test value was found between the groups at 4 weeks.

Subjective symptoms

A significant difference was observed between the VApal and placebo groups in the changes of the subjective symptom score for blurred vision at 1 and 2 weeks and in the total score for subjective symptoms at 1 week after drug administration. We found no significant differences between the groups for the other subjective symptoms. Improvement was noted for all 11 subjective symptoms except hyperemia in the VApal group, and in the placebo group, blurred vision, photophobia, itching, and tearing did not improve. Figure 3 shows the results of the evaluation of mean changes in five subjective symptom scores and the total score for subjective symptoms. Table 3 shows mean changes in all subjective symptom scores.

Table 3 Mean change in symptom score

	Week	Mean change		P-value
		Placebo	VApal
Dryness	1	−0.45±0.11	−0.73±0.11	0.0794
	2	−0.64±0.13	−0.79±0.13	0.3957
	4	−0.82±0.13	−0.91±0.13	0.6224
Eye fatigue	1	−0.33±0.11	−0.30±0.11	0.8483
	2	−0.48±0.12	−0.39±0.12	0.5923
	4	−0.55±0.12	−0.58±0.12	0.8629
Foreign body sensation	1	−0.10±0.14	−0.30±0.14	0.2780
	2	−0.36±0.13	−0.33±0.13	0.8683
	4	−0.33±0.15	−0.42±0.15	0.6693
Blurred vision	1	0.06±0.09	−0.36±0.09	0.0016
	2	0.03±0.12	−0.33±0.12	0.0299
	4	−0.21±0.13	−0.48±0.13	0.1321
Eye pain	1	−0.27±0.13	−0.21±0.13	0.7506
	2	−0.45±0.14	−0.24±0.14	0.2813
	4	−0.48±0.17	−0.33±0.17	0.5258
Photophobia	1	−0.06±0.09	−0.15±0.09	0.4646
	2	−0.09±0.10	−0.18±0.10	0.5276
	4	−0.18±0.10	−0.21±0.10	0.8359
Heaviness	1	0.00±0.11	−0.24±0.11	0.1277
	2	−0.09±0.13	−0.24±0.13	0.4199
	4	−0.39±0.13	−0.52±0.13	0.5025
Itching	1	−0.06±0.10	−0.24±0.10	0.1905
	2	−0.06±0.11	−0.36±0.11	0.0556
	4	−0.21±0.12	−0.36±0.12	0.3652
Ocular discomfort	1	−0.27±0.14	−0.24±0.14	0.8806
	2	−0.33±0.12	−0.27±0.12	0.7284
	4	−0.42±0.14	−0.55±0.14	0.5369
Eye discharge	1	−0.06±0.08	−0.12±0.08	0.5923
	2	−0.09±0.09	−0.27±0.09	0.1600
	4	−0.15±0.08	−0.33±0.08	0.1137
Tearing	1	−0.06±0.05	−0.15±0.05	0.2369
	2	−0.09±0.07	−0.12±0.07	0.7593
	4	−0.06±0.09	−0.12±0.09	0.6384
Hyperemia	1	0.00±0.10	−0.06±0.10	0.6602
	2	−0.06±0.12	−0.03±0.12	0.8551
	4	−0.21±0.11	−0.12±0.11	0.5719
Total score of the subjective symptoms	1	−0.82±0.31	−1.76±0.31	0.0351
	2	−1.52±0.35	−1.88±0.35	0.4695
	4	−2.03±0.45	−2.36±0.45	0.5983

Abbreviation: VApal, retinol palmitate.

Figure 3 Mean change in symptom score.

Notes: Mean change in symptom scores for dryness (A), blurred vision (B), heaviness (C), itching (D), and eye discharge (E) and total score for subjective symptoms (F) from baseline to 1, 2, and 4 weeks. *P<0.05. **P<0.01 versus placebo (unpaired t-test).
Abbreviation: VApal, retinol palmitate.

Safety assessments

Table 4 shows that adverse events occurred in three patients (9.1%) in the VApal group and two patients (6.1%) in the placebo group, and this difference was not significant. Furthermore, no significant difference was observed in adverse reactions, which did not occur in the VApal group and occurred in one patient (3%) in the placebo group. Adverse events with an expression rate of ≥1% in the VApal group were urine protein detection, arthritis, and nasopharyngitis. No serious drug-related adverse events occurred in any patient during the study. Slit-lamp examination, visual acuity testing, intraocular pressure measurement, funduscopic examination, and clinical blood and urine analyses indicated no clinical problems.

Table 4 Adverse events and adverse reactions

	Placebo	VApal
Adverse events, n (%)
No of subjects with adverse events	2 (6.1)	3 (9.1)
Eyelid edema	1 (3.0)	–
Dermatitis	1 (3.0)	–
Protein urine	–	1 (3.0)
Arthritis	–	1 (3.0)
Nasopharyngitis	–	1 (3.0)
Adverse reactions, n (%)
No of subjects with adverse reactions	1 (3.0)	0 (0.0)
Eyelid edema	1 (3.0)	–

Abbreviation: VApal, retinol palmitate.

Discussion

When mucin decreases owing to corneal and conjunctival disorders, the stabilization of the aqueous layer on the mucin layer is impaired, and dry eye results when the tear layer on the ocular surface becomes unstable and is no longer uniformly maintained.^3–5 A vicious cycle in which the instability of the mucin layer leads to further corneal and conjunctival epithelial damage occurs with dry eye, and mucin reduction has a major role in the onset and progression of this condition.⁶ We investigated the pharmacology of VApal and reported improvements in mucin abnormalities (RB staining evaluation) after VApal administration in experimental keratoconjunctival epithelial damage induced by n-heptanol in rabbits¹¹ and in dry eye models treated with alkali solution after the removal of lacrimal glands in rabbits¹⁰ and rats.¹² We also confirmed that VApal promotes mucin gene¹² and protein^8,12 expression as well as the recovery of conjunctival goblet cell numbers.^9,11 In addition, the dry eye therapeutic agents diquafosol sodium and rebamipide reportedly improve dry eye by decreasing mucin abnormality.^21–24 These results suggest that in the present study of human subjects, VApal improved mucin abnormality in the keratoconjunctival epithelium by promoting mucin expression on the ocular surface and the recovery of conjunctival goblet cells.

In this trial, one drop of VApal (500 IU/mL) or placebo was administered to dry eye patients six times daily for 4 weeks to examine the efficacy and safety of this treatment. This prospective, randomized, double-masked, placebo-controlled, Phase II trial is the first to be performed in Japanese patients with dry eye. The study population comprised a large proportion of middle-aged and aging women, a trend reflected in the clinical population of dry eye patients.^25,26 We enrolled subjects who showed no improvement after the administration of artificial tears during a 2-week washout period. In addition, we considered the cohort reliable because there were no significant differences in male-to-female ratio, presence or absence of Sjögren’s syndrome, age, staining scores, BUT, or Schirmer’s test value between the groups.

In general, hyaluronic acid is produced by corneal epithelial cells and corneal stromal cells, and it repairs corneal wounds by promoting the adhesion and extension of corneal epithelial cells.²⁷ We previously confirmed that VApal promotes hyaluronic acid expression in the cultured corneal epithelial cells of rabbits.⁷ In addition, the effectiveness of VApal in promoting wound healing (according to fluorescein staining evaluation) was confirmed by the results of our previous studies of experimental keratoconjunctival epithelial damage in rabbits¹¹ and dry eye models in rabbits¹⁰ and rats,¹² as well as in dry eye-like symptoms induced by vitamin A deficiency in rabbits.⁹ These results suggest that VApal improved wound healing in the corneal and conjunctival epithelium by promoting hyaluronic acid expression in the ocular tissue in addition to stabilizing the mucin layer as described earlier.

On the contrary, VApal has not been confirmed to improve BUT, which is an index for evaluating the stability of tears.²⁸ Mucin in tears is crucial to tear stability, and secretory mucin, MUC5AC, reportedly has a key role in reducing BUT.²⁹ In our examination of the expression change in mucin genes and protein subtype after VApal administration in a dry eye model in rats, we found that VApal promoted corneal rMuc4, conjunctival rMuc5AC, and conjunctival rMuc16 gene expression as well as MUC16 protein expression.¹² Although VApal may promote the expression of secretory mucin,^8,12 these results suggest that the expression of membrane-type mucin such as MUC16 was promoted more strongly. The results of the present study also suggest that VApal promotes membrane mucin expression. VApal administration significantly decreased RB staining score, which evaluates deficiencies in membrane mucin.^29,30 The results of another study showed that the thickness of the lipid layer of the tear film is correlated with BUT³¹ and that components that act on the meibomian glands that produce the lipid in the tear film may improve BUT. Therefore, VApal may not improve BUT because it does not promote secretory mucin expression or lipid production in the meibomian glands.

We observed no improvement in tear secretion after VApal administration. Schirmer’s test I is commonly used to diagnose dry eye, but because it is performed without anesthesia, it evaluates not only the amount of tear storage and basal secretion but also reflective secretion. This evaluation method is more pertinent in Sjögren’s syndrome and other conditions in which the lacrimal gland is damaged and tear secretion is decreased.¹⁷ As described earlier, we concluded that VApal mainly acted on the corneal and conjunctival epithelial layer of the ocular surface, not on the lacrimal glands or via a mechanism that increased tear production.

With respect to subjective symptoms, 11 of 12 subjective symptoms in the VApal group improved significantly after drug administration. In particular, scores for blurred vision and total score for subjective symptoms significantly improved in the VApal group compared with those in the placebo group. Therefore, these improvements are due to the effects of VApal. Decreases in subjective symptoms and objective signs of dry eye can contribute to improvements in both quality of life and treatment compliance in patients.

Improvements in the objective signs and subjective symptoms of dry eye were also observed in the placebo group in this study and were attributed to the D-α-tocopherol acetate and hypromellose (water-soluble polymer) contained in the placebo compound and the VApal ophthalmic solution. Therefore, although the direct effects of these compounds are unknown, the objective signs and subjective symptoms of dry eye may have improved owing to the antioxidant effect of D-α-tocopherol acetate^32,33 and the improved retention of ophthalmic solution in the eye enabled by hypromellose.³⁴ Synergistic effects might be expected using VApal in combination with these components.

We found no significant differences between the groups in the incidence of adverse events or adverse reactions. All adverse events and adverse reactions were mild and non-severe, and no patients discontinued the trial. These results show that VApal administration can be considered safe. The low occurrence of adverse reactions in the treatment group may be related to the fact that vitamin A is a biological component in tear fluid³⁵ and VApal ophthalmic solution contains no preservatives that can damage the eye.^36,37 Furthermore, clinical reports identified only mild eye pain¹⁷ or no adverse reactions^13,15 after VApal administration. Therefore, VApal is a potential new drug for the treatment of dry eye with few adverse reactions.

In recent years, a new treatment strategy for dry eye called tear film-oriented therapy has been proposed. This strategy does not treat symptoms but instead aims to restore healthy tears by targeting the damaged parts of tears.¹⁹ As a result, diquafosol sodium and rebamipide, which restore the mucin layer, were recently approved as therapeutic agents for dry eye. Diquafosol is a uridine triphosphate-related compound that is reported to be an agonist of the purinergic P2Y₂ receptor expressed in several ocular structures (palpebral and bulbar conjunctival epithelium, goblet cells and adipocytes, and ductal epithelial cells in the meibomian gland) and a contributor to water transfer and mucin secretion^21,22 Rebamipide is a quinolinone derivative that, similar to diquafosol, improves dry eye by promoting mucin secretion. This compound reportedly enhanced the gene expression of MUC1 and MUC4.^23,24 However, diquafosol sodium causes eye discharge and eye pain,^21,22 and rebamipide has been associated with dysgeusia.^23,24 Because VApal has fewer adverse reactions, it may become a preferred treatment for dry eye.

Conclusion

The results of this trial showed that the objective signs and subjective symptoms of dry eye were improved by the instillation of one drop of VApal ophthalmic solution (500 IU/mL) six times daily for 4 weeks. Furthermore, the tolerability of VApal ophthalmic solution in patients with dry eye was good. In conclusion, VApal ophthalmic solution is clinically useful for the treatment of patients with dry eye.

Disclosure

The authors report no conflicts of interest in this work.